View Clinical Trial (Medical Research Study)

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease - NCT00818662-19104(Clinical Trial 262793)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Philadelphia
State:  
PA
Zip Code: 19104
Conditions: Alzheimer´s Disease
Purpose: The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer´s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Study summary: Study visits: Each subject will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). The first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. Each subject must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain.
Criteria: Inclusion Criteria: - Written informed consent - subject (or subject´s legally acceptable representative) and caregiver who are willing and able to participate for the duration of the study - Diagnosis of probable Alzheimer´s Disease (AD) - Dementia of mild to moderate severity defined as mini-mental state examination (MMSE) 16-26 inclusive at the time of screening - Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset consistent with AD diagnosis - Ability to comply with testing and infusion regimen, including fluency in English or Spanish, adequate corrected visual acuity and hearing ability - On stable doses of FDA approved AD medication(s) for at least 3 months prior to screening. These medications must be continued throughout this study. - If receiving psychoactive medications (e.g. antidepressants other than monoamine oxidase inhibitors (MAOIs) and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc), must be on stable doses for at least 6 weeks prior to screening Exclusion Criteria (Reasons why it might not be appropriate to participate): - Any other forms of dementia - Medical issues that might increase the risk of treatment with IGIV, 10%, such as: 1. Significant problems with blood pressure, heart disease, clotting disorders, strokes or recent heart attacks 2. Evidence of current bleeding in the brain by MRI 3. Serious problems with the liver or kidneys 4. Allergies to blood products - Medical issues that might interfere with the evaluation of the treatment of dementia or might make dementia worse, such as: 1. Diabetes 2. Recent treatment with chemotherapy or immune suppression 3. The recent use of other investigational drugs, especially antibody therapy for AD 4. Severe headaches or psychiatric problems There are other reasons why it might not be appropriate to pariticipate in this trial. Please consult an investigator at one of the trial sites for details.
Study is available at: University of Pennsylvania
Philadelphia, PA 19104
United States

Primary Contact:
Edward Y Tan, Clinical Project Manager
Email: edward_tan@baxter.com
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.